The numbers come first. IHH Healthcare posted approximately $6 billion in revenue for 2025, operates 89 hospitals across 10 countries, and ranks No. 58 on Fortune's Southeast Asia 500 list. That scale gives CEO Prem Kumar Nair a platform most healthcare executives can only imagine — and he is using it to reframe what longevity medicine actually means in a rapidly aging Asia.
'There's no point in living longer if you're not healthy,' Nair told Fortune in a recent interview. It is a deceptively simple line, but it carries a strategic weight. One in four Asians will be older than 65 by 2050, according to the Asian Development Bank. A Stanford study published in April found that population aging accounted for 33.6% of the increase in disease burden across mainland China, Japan, Singapore, South Korea, and Taiwan. The market signal is unmistakable.
IHH's answer is 'Healthspan,' a preventive health and longevity program launched in July and currently available in Singapore. The program is built around clinical intervention — resistance training to prevent sarcopenia-related fractures, GLP-1 medications to address obesity-driven metabolic disease, and chronic disease management — not the supplement stacks and aesthetic treatments that dominate the consumer wellness industry. 'For many people, longevity means aesthetics: coloring your hair, and taking a whole lot of vitamins and supplements,' Nair said. 'But for a healthcare provider like us, longevity is anchored very strongly in clinical science.' He eventually hopes to expand Healthspan to IHH's nine other markets, including India, Turkey, and Greater China.
Alongside the longevity push, IHH is building ambulatory care centers — smaller, community-based facilities that handle procedures like endoscopies and total knee replacements without a hospital admission. Singapore's Parkway MediCentre in the Woodleigh district, offering chronic disease management and specialist consultations, is one example. 'We have transitioned from being a mega hospital player to a healthcare ecosystem player in all the countries that we are in,' Nair said.
The strategic shift is also a financial one. When Nair joined IHH in 2020 after 27 years at competitor Raffles Medical Group, he redirected the company away from the acquisition-heavy model that had defined its early years — a model that included the 2015 purchase of Globe Healthcare and the 2018 takeover of Fortis Healthcare. 'A lot of investors were asking us whether M&As were an efficient way to grow, since each time we grow inorganically, we have to integrate the different entities,' he said. Since taking the helm, IHH has added 4,000 beds through organic expansion.
IHH was incorporated in 2010 as a holding company for Malaysian sovereign wealth fund Khazanah Nasional Berhad's healthcare assets. Its 2012 dual IPO on Bursa Malaysia and the Singapore Stock Exchange raised $2 billion — the third-largest listing globally that year, behind only Facebook and Felda Global Ventures Holding.
The market has already voted on the organic-growth thesis: IHH's revenue trajectory and bed-count expansion suggest the discipline is paying off. What Nair is building now is something harder to replicate than a hospital acquisition — a clinical ecosystem embedded in communities, calibrated to the specific disease burden of an aging, increasingly affluent Asia. Capital rewards clear rules, and in healthcare, the clearest rule of all is that demographics do not negotiate.
